Development of a cross-serotype Adenovirus vaccine

Period of Performance: 09/29/2015 - 04/28/2016


Phase 1 SBIR

Recipient Firm

Biological Mimetics, Inc.
Firm POC
Principal Investigator


We propose to develop a single antigen that stimulates cross-protective immunity against Ad4 and Ad7 serotypes as a method of reducing the costs associated with manufacturing the vaccine. By using our proprietary Immune Refocusing Technology (IRT), we will design and engineer a panel of recombinant IRT adenoviruses that each contain mutated codons at one epitope. Sera from mice immunized with the antigens will be tested for neutralization of Ad4 and Ad7, as well as Ad 3, 14, and 21. 2nd-generation IRT antigens containing multiple combinations of antigens identified in the leading antigens will be examined in a future study.